EpiDOSE is an acronym for the Epinephrine Dose: Optimal versus Standard Evaluation clinical trial.
It is a randomized controlled trial initiated by Dr. Paul Dorian and Dr. Steve Lin at St. Michael’s Hospital, in collaboration with physicians, paramedics, patients, families, and researchers. The study is funded by the Canadian Institutes of Health Research, Canada’s federal funding source for health research. Meet our team here
The goal of EpiDOSE is to test how effective a lower total dose of epinephrine is compared to the current standard on survival in adults who experience an out-of-hospital cardiac arrest. The current usual dose (or standard dose) that most patients receive is 1mg of epinephrine every 3 to 5 minutes until return of spontaneous circulation or termination of resuscitation (unlimited total). The lower dose used in this study is up to 2mg total. Currently, the optimal total dose of epinephrine during an out-of-hospital cardiac arrest is unknown.
Study enrollment will begin in 2022 and last for approximately 5 years.
The best total dose of epinephrine during an out-of-hospital cardiac arrest is unknown. Research has suggested that the standard total dose of epinephrine may be too high and that a lower dose strategy may be beneficial for long-term survival.
Emergency medical services in British Columbia and Ontario, including Peel, Halton, Toronto, and Ottawa.
